- Sight Sciences (SGHT, Financial) announces the OMNI® Edge Surgical System debuting at ASCRS 2025 in Los Angeles, with enhanced features.
- The system offers nearly double the viscoelastic capacity (21 µL) of its predecessor, with new TruSync™ technology.
- Over 300,000 procedures have been performed with OMNI systems, highlighting its leadership in canal-based minimally invasive glaucoma surgery (MIGS).
Sight Sciences, Inc. (SGHT), a leader in eyecare technology, is set to introduce its latest innovation, the OMNI® Edge Surgical System. This expansion of the OMNI® product family will be showcased at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Los Angeles from April 25-27.
The OMNI Edge system incorporates TruSync™ technology, which synchronizes the delivery of viscoelastic with surgeon movements, and offers an increased capacity of 21 µL, nearly double that of the previous OMNI system's 11 µL. This design is geared toward minimally invasive glaucoma surgeries (MIGS) addressing all three areas of resistance in the aqueous outflow system: trabecular meshwork, Schlemm's canal, and collector channels.
Moreover, the OMNI Edge can function as a standalone procedure or in conjunction with cataract surgery for the treatment of primary open-angle glaucoma (POAG). The company reports that its original OMNI platform has seen over 300,000 successful procedures, establishing it as a frontrunner in canal-based MIGS.
"OMNI Edge represents the next step in providing the most comprehensive and versatile implant-free MIGS technology," stated Christine Funke, MD, following early clinical trials.
The system will be exclusively available in the United States, offering surgeons a choice between the original OMNI and the new Edge version, thus catering to varied surgical preferences. This strategic expansion underlines Sight Sciences' commitment to advancing ophthalmic technology and improving patient outcomes.
